ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.
Biopharm are increasingly assessing the threat counterfeiting and diversion pose to emerging biotechs when planning an acquisition, according to a white paper.
B. Braun is recalling lots of its injectable anticoagulant, Heparin, manufactured in 2008, after finding a sample used to manufacture Heparin Sodium USP active pharmaceutical ingredients (APIs) was contaminated.
Lonza is seeing increased capacity utilisation and project pipelines in custom manufacturing but warned more stringent regulatory approval is creating volatility.
Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
Horizon Discovery will use its X-MAN human disease cell line models to identify patients likely to benefit from Cylene Pharmaceuticals’ candidate cancer drug, CX-4945.
A developmental purification system for Antibody-Drug-Conjugates will be launched by ADC Biotechnology (ADBC), a spin off from Reaxa, which promises reduced manufacturing costs for “magic bullet” cancer drugs.
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
Cell Biosciences plans to gain ground in the protein-based drugs market by acquiring Convergent Bioscience at the end of October for a cash sum of $12m (€8.6m.)
SGS Life Sciences will roll out new biologics testing capabilities across its network in bid to be the world’s number one contract biopharmaceuticals testing laboratory by 2014.
Beta-Pro is addressing rising demands from drug discovery and research institutes in the hepatocyte market by expanding its site at the University of Virginia Research Park, US, with a new GLP facility.
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
SoluBest and Dr Reddy’s Laboratories are joining forces to develop a proprietary formulation of one of SoluBest’s pipeline compounds using its Solumer platform.
China leads the field in 'potential future' API suppliers, positioning it to become a dominant force as these companies develop, Thomson Reuters said at CPhI 2010.
Galapagos’ acquisition, Argenta, has signed up to a $46m cancer drug discovery service deal with Janssen Pharmaceutica, aimed at delivering novel cancer drug candidates.
Belgium-based biopharmaceutical company, ThromboGenics, has signed a ten-year supply agreement with MSD Biologics, to produce microplasmin for the treatment of retinal disorders.
RXi and EyeGate lift the lid on ocular delivery of RNAi therapeutics for retinal disorders as the two firm’s team up to provide a unique needle-free solution.
Cost-effective, large-scale production of oncology drug Taxol (paclitaxel) intermediates could eventually be achieved using engineered Escherichia coli.
RXi Pharmaceuticals and EyeGate Pharma will unite to develop non-invasive, needle-free ocular delivery of RNAi therapeutics using the EyeGate II system for the treatment of retinal disorders.
Anglo-German company Evotec is joining forces with Almirall to identify small molecule modulators of an ion channel target involved in respiratory diseases.
Sheffield Bio-Science takes on responsibility for global sales, distribution and development of Girus Life Sciences’ chemically defined Regocel supplements.
Reengineering erythropoietin (EPO) as an immunoglobulin G (IgG) fusion protein enables penetration of the blood-brain barrier (BBB) in mice, according to researchers.
DSM’s microbial fermentation CMO business unit and UK-based biopharmaceutical company, PolyTherics, have formed an agreement to develop and manufacture PolyTherics’ lead ‘biobetter’ product, HiPEG IFN a-2a.
Life Technologies has concluded license agreements, providing rights to its proprietary Chinese hamster ovary (CHO) cell lines for production of recombinant proteins used as therapeutic agents and vaccines.
In an exclusive Q&A Mark Rohlfing, Almac’s director of Quality, updates Outsourcing-pharma on the firm’s new North American HQ, growth plans and US recruitment drive.
Pall has ended fiscal 2010 with strong set of sales after recovering pharmaceutical industry demand for bioproduction tech maintained its momentum in Q4
Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.